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Background: Within a large subset of heart failure, cardiac ubiquitin-proteasome system (UPS) 
inadequacy is causative. A vital UPS regulator is the COP9 signalosome (CSN). The CSN holocomplex is 
formed by 8 unique protein subunits (COPS1~COPS8) and regulates Cullin-RING ligases via Cullin 
deneddylation. Cardiomyocyte-restricted knockout (cko) of Cops8 causes massive cardiomyocyte 
necroptosis via the RIPK1-RIPK3-MLKL pathway, resulting in dilated cardiomyopathy (DCM) and 
shortened lifespan in mice. CSN’s deneddylase resides in COPS5 and Cops5-cko has not been explored. It 
is important to investigate how the necroptotic pathway within cardiomyocytes is activated in Cops8-
cko mice as cardiomyocyte necroptosis has been shown to play an important role in cardiac 
pathophysiology. Protein kinase Cδ (PKCδ) regulates cardiomyocyte survival but its potential 
involvement in cardiomyocyte necroptosis remains unknown. To fill these gaps, we conducted the 
present study to examine the hypothesis that Cullin deneddylation suppresses cardiomyocyte 
necroptosis but PKCδ promotes the activation of cardiomyocyte canonical necroptotic pathway in 
Cops8-cko mice.    
 
Methods and Results: Cops8-cko, Cops5-cko, or Cops8+Cops5 double cko (Double-cko) initiated in adult 
mice were achieved using a tamoxifen-inducible Cre-LoxP system. Echocardiography performed 21 days 
after tamoxifen withdrawal showed no significant difference between 2 control groups: Myh6-
MerCreMer transgenic mice (MCM) and Cops5-floxed/Cops8-floxed mice. Compared with MCM, all cko 
groups displayed DCM, but the severity in the Cops5-cko and Double-cko groups were similarly greater 
than that in the Cops8-cko group. Kaplan-Meier survival analyses revealed that the post-tamoxifen 
lifespans of Cops5-cko and Double-cko mice (median, 42 days) were comparably shortened but 
significantly shorter than that of Cops8-cko mice (81 days). We observed a greater proportion of 
cardiomyocytes positive for Evans blue dye uptake and greater increases of myocardial CD45 proteins in 
Cops5-cko and double-cko mice than in Cops8-cko mice. Both Cops8-cko and Cops5-cko mice exhibited a 
2.5-fold upregulation of myocardial PKCδ. Coupling heterozygous germ-line knockout of PKCδ with 
perinatal Cops8-cko decreased the activation of the RIP1-RIP3-MLKL pathway, attenuated cardiac 
malfunction, and delayed mouse premature death induced by Cops8-cko. 
 
Conclusions: Cullin-deneddylation activity is required for the CSN to suppress cardiomyocyte 
necroptosis; upregulation of PKCδ contributes to activation of the RIPK1-RIPK3-MLKL pathway by Cops8 
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1. INTRODUCTION  
1.1. The ubiquitin-proteasome system  
The ubiquitin-proteasome system (UPS) is one of the two major protein degradation pathways 
in cells. Abnormalities within the UPS have been implicated in a broad spectrum of human 
diseases, more recently within cardiac pathophysiology like cardiomyopathies and congestive 
heart failure1-4. The UPS consists of ubiquitination and the subsequent proteasome-mediated 
degradation of the ubiquitinated protein. Ubiquitination is catalyzed by a specific enzymatic 
cascade including ubiquitin (Ub) activating enzyme (E1), Ub conjugating enzyme (E2), and Ub 
ligase (E3). This enzymatic cascade will charge and transfer a Ub protein to a substrate protein 
molecule that is damaged, misfolded, or otherwise unneeded within the cell. Multiple rounds of 
such reactions attach a chain of Ubs to the substrate protein and the polyubuiquitin tag acts as 
a signal to the proteasome to degrade the ubiquitinated substrate. The E3 ligase determines 
the specificity of substrates in ubiquitination and is a rate-limiting step, which will be discussed 
in depth further in the next section. Overall, the benefit of the UPS is that it recycles toxic or 
unneeded regulatory proteins into small chains of amino acids that can then be reused. 
Upwards of about 80-90% of all proteins will be regulated through the UPS and therefore, there 
are broad implications in virtually all signaling pathways within the cell.  Protein homeostasis, or 
proteostasis, is maintained through highly regulated protein synthesis, folding, trafficking, post 
translational modification, localization, and degradation; however, proteotoxic stress refers to 
damaged or misfolded proteins and organelles and their effect on the cell. Increased 
2 
 
proteotoxic stress can result from genetic causes, environmental stressors, the aging process, 
etc. and can cause functional changes in the tissue or organ5. 
1.2. Cullin-RING ligase, neddylation, and deneddylation 
As mentioned above, E3 ligases determine the substrate specificity in ubiquitination and, in 
general, polyubiquitination licenses the protein for degradation by the 26S proteasome, 
thereby determining whether the substrate protein molecule can be degraded by the UPS. 
More than 600 E3 ligases exist in the eukaryotic cell. The largest subset of E3 ligases, Cullin Ring 
Ligases (CRLs), account for 419 of the E3 ligases and approximately 20% of the ubiquitin-
dependent degradation of proteins6, 7. CRLs directly allow for a transfer of a charged ubiquitin 
from the E2 to the substrate. All CRLs share a similar core structure where the Cullin serves as a 
molecular scaffold that binds to an adaptor protein and a substrate receptor module at the N-
terminus of the Cullin and a RING protein at the C-terminus of the Cullin. The substrate 
receptor module determines the substrate specificity of the CRLs. Once fully assembled, a 
ubiquitin-like protein NEDD8 (Neural precursor cell Expressed Developmentally Down-regulated 
8) will be covalently attached to a key lysine residue at the C-terminus of the Cullin via a 
ubiquitination-like process, known as neddylation. Cullin neddylation activates the CRL. The 
reverse process, Cullin deneddylation, is the cleavage of the NEDD8 protein from the CRL and 
deactivates the CRL. Cullin neddylation is essential to CRL assembly and activation, while Cullin 
deneddylation is essential to CRL disassembly and deactivation. Cullin deneddylation is 
performed by the Cop9 signalosome and will be detailed further in the next section. Timely 




1.3. The COP9 signalosome and its bona fide biochemical activity 
The COP9 (COnstitutive Photomorphogenesis 9) signalosome (CSN) was first discovered in the 
Arabidopsis thaliana, a small flowering plant, and is highly conserved in eukaryotes, from yeast 
to humans and plays a role in a wide variety of signaling pathways like cell cycle progression, 
DNA repair, nuclear export, and immune responses8-11. The CSN is a vital ubiquitination 
regulator in the UPS and consists of eight canonical protein subunits (COPS1/CSN1 through 
COPS8/CSN8). The CSN’s bona fide biochemical activity is as a deneddylase- or deconjugation of 
a NEDD8 protein from a neddylated Cullin. Thus, correct functioning of the CSN allows for 
regular disassembly of these CRLs when appropriate, which is vital to correct ubiquitination and 
the subsequent degradation or signaling fate of an extensive range of cellular substrates as well 
as toxic, cytosolic misfolded proteins. For proper CSN biochemical activity, all eight subunits are 
required1. In situations where a subunit is depleted, the other subunits are depleted to various 
degrees and Cullin deneddylation is impaired, illustrating that the deneddylase activity of the 
CSN requires the formation of the CSN holocomplex by the eight subunits. Loss of CSN function 
and Cullin deneddylation leads to self-ubiquitination and destabilization of many substrate-
recognizing adaptors in CRLs and thereby accumulating their substrates (Figure 1)12-15. The 
COPS5 subunit contains the deneddylase site of the CSN, but COPS5 only exerts Cullin 
deneddylation activity when it is situated in the fully assembled CSN holocomplex consisting of 








Figure 1. A working model for the role of the COP9 Signalosome (CSN) in the regulation of the 
catalytic dynamic of Cullin-RING ligases (CRLs). A. Under normal condition, the CSN holocomplex 
formed from the 8 unique protein subunits (CSN1 through CSN8) removes the Nedd8 from the 
neddylated Cullin, thereby inactivates and dissembles the CRL that has completed ubiquitinating a 
substrate protein (Substrate-1) recruited by substrate receptor 1 (SR1), allowing formation of a new 
CRL with a new SR (SR2) to recruit a new substrate (Substrate-2) for ubiquitination. B. Defect in the 
formation of the CSN holocomplex, such as depletion of a subunit due to genetic mutation, may 
increase the abundance of certain species of mini complexes composed of some of the CSN subunits 
but reduces or loses the deneddylase activity, impairing Cullin deneddylation; Cullin deneddylation by 
the CSN can also be inhibited by small molecules (e.g., CSN5i-3). When Cullin deneddylation is lost, 
the exchange of SRs in CRLs will be compromised and as a result, the catalytic dynamic of CRLs will be 
stalled, even leading to autoubiquitination and destruction of CRL components (e.g., SR). (Adopted 






1.4. Necroptotic pathways 
Many studies have shown that cardiomyocyte death is a major turning point in the genesis of 
heart failure17, 18. Severe dysfunction of cellular proteostasis leads to changes in cellular 
functioning and in extreme cases leads to cell death19. In a functioning heart, cardiomyocytes 
need to withstand high amounts of thermal and mechanical stress and are therefore more 
sensitive to cell death if proteostasis is not adequately maintained. Loss of cardiomyocytes in 
the form of apoptosis and necrosis can be the tipping point during the progression from various 
forms of primary heart disease to heart failure. Accordingly, ablation of many of the CSN 
subunits or the CSN holocomplex, either genetically or chemically, has been shown to induce 
massive cell death20-24. Recently, it has been found that not all necrosis is accidental, but 
multiple forms of highly regulated necrosis are present. Necroptosis, the earliest identified 
regulated death receptor-triggered necrosis, is perhaps the most studied thus far. The canonical 
necroptotic pathway, the receptor-interacting protein kinase 1 (RIPK1)-RIPK3-MLKL (mixed-
lineage kinase domain-like protein) pathway, is activated via TNFα ligand binding to the TNFR1 
receptor (Figure 2)15. Based on the cellular environment, specifically with the absence of 
correct Caspase 8 activity, RIPK1 will act as a molecular checkpoint, where specific 
phosphorylated sites will either activate as in the case of Ser166-phosphorylated RIPK1 (pS166-
RIPK1) or suppress in the case of Ser321-phosphorylated RIPK1 (pS321-RIPK1) in the kinase 
activity of RIPK1. With activation of this pathway, activated RIPK1 binds to and phosphorylates 
RIPK3, which in turn recruits and phosphorylates MLKL at site Ser345. Ser345-phosphorylated 
MLKL (pS345-MLKL) will then translocate to the plasma membrane and oligomerize creating 
pores, which allow for the cell membrane to become permeable to extracellular ions and water 
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as well as releasing intracellular contents into the extracellular space, thereby causing 
subsequent cell swelling and rupture while also releasing cellular contents that trigger 
inflammatory responses. Accordingly, potential links between necroptosis and the catalytic 







Figure 2. An illustration for the potential signaling events and outcomes after the activation of 
TNFR1. The binding of TNFα to TNFR1 induces the formation of a membrane-bound assembly knowns 
as Complex I which is associated with the cytoplasmic tail of TNFR1 and contains TRADD, RIPK1, 
TRAF2, LUBAC, and cIAP1/2, where LUBAC adds linear ubiquitin chains to RIPK1 and other proteins, 
whereas cIAP1/2 catalyze the addition of K63-linked polyubiquitin chains to RIPK1 and other proteins 
within Complex I. The ubiquitinated RIPK1 functions as scaffold to recruit NEMO and TAK1, leading to 
the activation of NFκB and MAPK pathways, respectively and promotes cell survival and inflammation 
(A). Complex I can be transformed into the secondary cytosolic Complex IIa and IIb to signal for 
apoptosis (B) or necroptosis (C), respectively. B, Caspase-8 activity in Complex IIa determines 
downstream signaling toward an apoptotic outcome and simultaneously prevents necroptosis by 
cleaving RIPK1 or RIPK3. C, In Complex IIb, the absence or inactivation of caspase-8 triggers 
autophosphorylation of RIPK1, which in turn binds and phosphorylates RIPK3; phosphorylated RIPK3 
recruits and phosphorylates MLKL, leading to MLKL’s translocation to the plasma membrane where 
MLKL oligomerizes and forms pores, allowing an influx of extracellular ions and water into the cell 
that causes cell swelling and rupture, and the release of cellular contents triggers proinflammatory 




1.5. Why is it important to study the CSN in the heart? 
The UPS is both implicative and causative in a broad spectrum of diseases, more recently within 
cardiac pathophysiology. Studying the mechanisms that regulate the UPS, like CRLs and the 
CSN, is essential to understanding and pursuing this degradation pathway for promising 
therapeutic benefits25-27 Using classic mouse models of arrythmogenic right ventricular 
dysplasia/cardiomyopathy (ARVD/C), others have shown that these hearts have reduced 
junctional localization of Cops6, which impacts how desmosome and gap junctions are able to 
communicate electrically and form structurally and ultimately destruction of the desmosome 
occurs subsequently. They also showed that loss of Cops6 in hearts lead to increased 
neddylated CRLs. Down regulation of Cops6 has been found in human hearts with ARVD/C and 
down regulation of Cops6 was sufficient to cause ARVD/C in mouse models28, which 
mechanistically links dysregulation of the CSN to human heart disease. However, their study did 
not look into deneddylation activity, holocomplex levels, or cell death within the Cops6 
knockout animals, which will be important.   
1.6. Cops8-cko mice provide a valuable model for studying inadequate PQC in cardiac 
pathophysiology 
Using a perinatal cardiomyocyte-restricted knockout of Cops8 (Cops8-cko) in mice, our lab has 
verified that Cullin deneddylation is impaired in cardiomyocytes and that necroptosis is a 
mechanistic link between inadequate protein quality control mechanisms and the development 
of cardiac pathophysiology20. In the Cops8-cko mice, Cullin deneddylation dysfunction is the 
first noticeable impairment. After which, both the UPS and the autophagic-lysosomal pathway 
(ALP) become dysfunctional, leading to massive necroptotic cardiomyocyte death via the RIPK1-
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RIPK3-MLKL pathway, a dilated cardiomyopathy phenotype, and a shortened lifespan20, 29. 
Accordingly, even a moderate downregulation of Cops8, using a hypomorphic Cops8 model 
causes similar effects22, 30. Hence, our lab has shown that the CSN holocomplex suppresses the 
cardiac RIPK1-RIPK3-MLKL necroptotic pathway in vivo29. Using genetic or chemical inhibition of 
core signaling proteins in the RIPK1-RIPK3-MLKL pathway, our lab has shown the promising 
therapeutic benefit of suppress0ing this inflammatory-type of cell death and subsequent 
cardiac pathological remodeling29. Furthermore, the Cops8-cko mouse model offers us a 
valuable tool for studying the prevention and effective treatment of cardiomyocyte necroptotic 
cell death, which mechanisms are currently poorly understood.  
1.7. PKCδ and cardiomyocyte death 
Protein kinase Cs (PKC) are an important enzyme family consisting of at least eleven closely 
related serine-threonine kinase enzymes encoded by the Prkcd gene31. These PKC enzymes 
have a highly conserved carboxy terminal kinase domain with a differing amino terminal 
regulatory region32, 33. Once these PKC enzymes are newly synthesized, they remain in a 
dormant state and become activated by posttranslational modification at distinct sites by 
second messengers, like phorbolesters and phospholipids. Once activated, PKCs will translocate 
to membranous sites, like the mitochondria or plasma membrane34, 35. A specific isoform in the 
novel group of PKCs, protein kinase C-delta (PKCδ), is expressed in many tissues, but expression 
seems to be localized to the atria of the heart with a presence in the ventricles, mostly in the 
membrane fraction36. PKCδ is thought to play a role in signaling that stimulates contraction but 
has become more notoriously known as a pro-death kinase, playing important roles in the 
apoptotic and necroptotic signaling pathway in response to oxidative stress37. Typically, PKCδ is 
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a lipid-dependent enzyme that, once activated, phosphorylates substrates in the cytosol; 
however, depending on the specific physiological stimuli, like oxidative stress, PKCδ becomes 
lipid-independent, changes substrate specificity and is thought to translocate to the 
mitochondria to decrease ROS generation by preventing the opening of the transition pore and 
activation of KATP channels to allow proteasome activity to continue normally, which will then 
degrade PKCδ38, 39. It has also been postulated that the overall levels of PKCδ (and other PKCs) 
are regulated by the proteasome during stressful stimuli40. PKCδ, in the presence of oxidative 
stress, causes changes in cardiac contraction and has shown to contribute to ventricular 
remodeling41. Transient episodes of ischemia activate PKCδ; however, inhibition of PKCδ during 
reperfusion of myocardial infarction is cardioprotective42, 43. Identifying therapies that regulate 
PKCs have become increasingly popular. Oxidative stress is high during apoptosis and 
necroptosis, and PKCδ has been explored in the context of apoptosis, but the relationship 
between PKCδ and necroptosis or the RIPK1-RIPK3-MLKL necroptotic pathway is obscure.  
1.8. Hypothesis and specific aims 
The overarching goal of this project is to aid in the current comprehension of molecular and 
cellular mechanisms that lead to heart failure in hopes of finding effective therapeutics. This 
project is aimed to 1) compare phenotypic differences between three CSN subunit 
cardiomyocyte-restricted knockout models: Cops8-cko, Cops5-cko, a double gene knockout 
(Cops8 + Cops5) in vivo. Any shared phenotypes between the models will be implied from the 
loss of the Cop9 signalosome holocomplex and Cullin deneddylation. However, differences in 
phenotypes are presumably from subunit-specific functions outside of the holocomplex. This 
project is also aimed to 2) preliminarily examine the role of PKCδ in the context of 
11 
 
cardiomyocyte necroptosis induced by Cops8-cko. This is to test the hypothesis that Cullin-
deneddylation activity is required for the CSN to suppress cardiomyocyte necrosis and that 





2. MATERIALS AND METHODS 
2.1. Animal Models 
All procedures involving animals were approved by the Animal Care and Use Committee of the 
University of South Dakota and conform to the NIH Guide for the Care and Use of Laboratory 
Animals. All in vivo studies were performed in age-matched, evenly sexed mice in the C57BL/6J 
background (referred to as B6; #000664, The Jackson Laboratory). Two cardiomyocyte specific 
Cops subunit knockout models were used: a perinatal knockout and an adult (inducible) 
knockout. For perinatal Cops8-cko, we used exactly the same perinatal Cre-LoxP strategy as we 
previously reported 20. The mice harboring the Cops8 floxed allele (Cops8FL/FL) were originally 
generated by Dr. Wei’s lab44, where the exons 4 through 6 of the Cops8 gene is flanked by two 
loxP sites. The Cops8FL/FL mice were crossed with a transgenic mouse expressing the Cre 
recombinase driven by the mouse alpha-myosin heavy chain gene promoter directing 
expression of Cre recombinase to cardiomyocytes (referred to as αMyHC-Cre or Myh6-Cre; # 
018972, The Jackson Laboratory). CSN5 (AKA, Jab1) is encoded by COPS5. Dr. R. Pardi generated 
the mouse with a Cops5-floxed allele in which exon 2 is flanked by 2 LoxP sites inserted in the 
introns sandwiching exon 2. Cre-mediated recombination effectively removes the exon 2, 
resulting in an early frameshift and translation termination45. This mouse model has since been 
successfully used for conditional CSN5 knockout in T cells,45 B cells,46 Schwann cells,47 and 
hepatocytes.48 So far, no reported studies have investigated Cops5-cko. We have acquired 
Cops5-floxed mice (Cops5flox/flox) from Dr. Pardi for studies proposed here. The same floxed 
mice used above were used for the adult, inducible knockouts and will be described in Section 
2.2. The PKCδ is encoded by the PRKCD gene. Mice with global knockout of the Prkcd gene 
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(PKCδ-KO) were purchased from The Jackson Laboratories (Stock #028055). PKCδ-KO mice lack 
the initiation codon in the exon 2 of Prkcd, resulting in a null allele49. Since homozygous 
knockout of Prkcd (Prkcd-/-) caused adverse effects (data not shown), heterozygous PKCδ-KO 
(Prkcd+/-) was used for the PKCδ-KO rescue experiments, in which perinatal Cops8-cko was 
introduced into Prkcd+/- and Prkcd+/+ background via cross-breeding and littermates were used 
for comparisons.   
2.2. Tamoxifen Treatment to Induce CKO in Adult Mice  
Induction of cardiomyocyte-specific knockout of Cops8 (Cops8-cko), Cops5 (Cops5-cko), or both 
genes (a double knockout of Cops8 and Cops5 henceforth referred to as Double-cko) in adult 
mice was achieved using a tamoxifen-inducible Cre-LoxP system where the transgenic (TG) 
mutant estrogen receptor sandwiched Cre (MerCreMer) was used as reported by others50. 
MerCreMer (MCM) is sequestered in the cytoplasm as it is not sensitive to the endogenous 
estrogen, but it can be bound by tamoxifen and thereby translocated from the cytoplasm to the 
nucleus where the MCM exerts its Cre recombinase activity. Both of Cops8- and Cops5-floxed 
mouse models were crossed with a TG mouse expressing the MCM driven by the mouse alpha-
myosin heavy chain gene promoter [B6.FVB(129)-Tg(Myh6-Cre/Esr1*)1Jmk/J; also known as αMHC-
MerCreMer or Myh6-MerCreMer] (JAX stock #005650; Jackson Labs)51. At two months of age, 
when physiological development is mostly complete, regular chow was switched out with a 
chow containing tamoxifen citrate (40 mg/KG; TD.130859 Envigo) and the mice were fed ad 
libitum for 14 days. Neither control nor experimental animals died from this tamoxifen 
administration regime. A schematic is presented below to show the timeline of treatments and 





Figure 3. A schematic for the design of experiments using the tamoxifen induced cko in adult mice. 
All adult mice were subjected to 14 days of tamoxifen administration via chow as illustrated. After 
tamoxifen administration, mice were subjected to EBD injections and subsequent perfusion fixation 
and tissue sampling for confocal microscopy (A), tissue sampling for biochemical analysis (B), or 
echocardiography and subsequent Kaplan-Meier survival analysis (C).  
 
2.3. Western Blot Analysis 
Western blotting was performed as previously described20. In brief, proteins were extracted 
from frozen ventricular myocardial tissues, homogenized in sampling buffer (1.0M Tris-HCl (pH 
6.8), 10% SDS, and 10% glycerol) containing a cocktail of protease inhibitors (#T-2496, AG. 
Scientific, San Diego, CA) to inhibit subsequent protein degradation, centrifuged for 10 minutes 
at 12,000g at 4°C, and supernatant was then collected. Protein concentration was measured 
using the bicinchoninic acid (BCA) assay (#23225, Themo Fisher Scientific). Polyacrylamide gels 
were made in house and 2,2,2-trichloroethanol (#139445000 , ACROS Organics) was added to 
the resolving gel for later florescent imaging of protein loading52. Equal amounts of protein 
sample were resolved by SDS-PAGE, transferred to PVDF membrane, and then membrane was 
blocked for 1 hour (in 5% milk), washed 3 times in PBST (TBST if phosphorylated protein) for 5 
minutes, incubated with appropriate primary antibodies for 12 hours on rocker (overnight in 4° 
fridge) (primary antibodies used are listed in Table 1), washed 3 times in PBST/TBST for 5 
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minutes, incubated with horseradish peroxidase–conjugated (HRP) secondary antibodies 
(Mouse: 115-035-003, Rabbit: 111-035-003, Goat: 305-035-003, Jackson ImmunoResearch) for 
1 hour, washed 3 times in PBST/TBST for 5 minutes, and Chemiluminescence (34578, Thermo 
Fisher Scientific) substrate was added to membrane and membrane was imaged via a 
ChemiDoc MP Imaging System (Bio-Rad). The signal was quantified and normalized to loading 
control, Stain-Free total proteins, using Image Lab 6.0 software (Bio-Rad).  
Table 1. Primary Antibody List 
Primary Antibody Vendor Catalog Number Dilutions Used 
CSN5 Bethyl Laboratories A300-014A 1:1000 
CSN8 Santa Cruz sc-47976 1:1000 
CD45 R&D Systems AF114 1:500 
PKCδ Santa Cruz sc-8402 1:1000 
Total RIPK1 Cell Signaling 3493s 1:1000 
Total RIPK3 Cell Signaling 14401 1:1000 
Total MLKL Cell Signaling 37705 1:1000 
pS166-RIPK1 Cell Signaling 31122S 1:500 
pS321-RIPK1 Cell Signaling 83613S 1:500 
pS345-MLKL Cell Signaling 37333s 1:500 
 
2.4. Evans Blue Dye (EBD) Uptake Assay and Confocal Microscopy  
EBD uptake assay was performed as previously described20, 53. In brief, EBD (#314-13-6, 
MilliporeSigma) solution (10 mg/mL dissolved in normal saline) was injected intraperitoneally 
(100 g/g of body weight). 12 hours later, the mouse was anesthetized, and the circulatory 
system was slowly perfused with both PBS to clear remaining blood and then freshly made 4% 
paraformaldehyde (PFA) to fix the tissue. Atria and fat were removed from heart and the 
ventricular myocardium was placed in 4% PFA for 12 hours on rocker (overnight in 4° fridge), 
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washed with PBS and then subsequently placed in 40% sucrose for 12 hours on rocker 
(overnight in 4° fridge). The myocardium was then embedded in O.C.T. (#23-730-571, Fisher 
Scientific) and quickly frozen on the surface of methanol/dry ice. 7m cryosections were 
collected and stained with phalloidin-fluorescein conjugate (#20478, Cayman Chemicals) and 
DAPI fluoromount (#0100-20, Southern Biotech) to fluoresce F-actin (cell membrane) and 
nuclei, respectively. Multiple confocal images were taken at X20 magnification and merged into 
one final image. The excitation wavelength used was 499 and emission wavelength used was 
680nm. The total staining of auto fluorescent EBD positive cells, red, was then normalized to a 
control, the total staining of cell membrane, green, from representative images from 4 
mice/genotype.  
2.5. Echocardiography 
The 2D-guided M-Mode echocardiography was performed as previously described20, 54. In brief, 
mice were anesthetized by inhalation of isoflurane (4.0% for induction and 1.5~2% for 
maintenance) via a nose cone. Chest hair was removed using Nair and transthoracic 
echocardiograph was recorded using the Vevo2100 echocardiography system (Visual Sonics) 
with a 32–56 MHz transducer (MS550s). A 2D short axis view was recorded at the papillary 
muscle level. The left ventricle morphometric and functional parameters were analyzed later 
using Vevo LAB 5.6.0 software (Visual Sonics). Derived parameters were calculated using the 
following calculations stroke volume (SV) equals end diastolic volume minus end systolic 
volume, Fractional Shortening (FS) equals end-diastolic left ventricular internal diameter minus 
end-systolic left ventricular internal diameter divided by end-diastolic left ventricular internal 
diameter times 100, Ejection Fraction (EF) equals SV divided by end diastolic volume times 100, 
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and Cardiac Output (CO) equals stroke volume times heart rate. 
2.6. Statistical analysis  
Unless otherwise indicated, data of continuous variables are presented as scatter dot plots with 
mean ± SEM superimposed. Differences among three or more groups were evaluated using 
one-way ANOVA followed by Tukey test for pairwise comparisons. A p-value < 0.05 was 
considered statistically significant. Kaplan-Meier survival curves significance testing was done 
using Log-Rank (Mantel-Cox) test between two groups. If more than two groups were being 
analyzed in a Kaplan-Meier survival curve, the p-value significance level was adjusted using 
Bonferroni corrected p-value thresholds to correct for multiple statistical testing between 
groups. The GraphPad Prism software (Version 9.2; GraphPad Software, San Diego, CA 92108) 





3.1. Verification of tamoxifen-inducible cardiomyocyte-specific knockouts 
The CSN requires all the eight canonical protein subunits for the holocomplex formation and 
proper CSN deneddylase functioning8. Although much is known about CSN subunit knockout 
phenotypes in certain tissue types, the different subunits’ knockout effect on the heart is 
largely unknown. To elucidate this, three mouse models of CSN subunit cardiomyocyte-specific 
knockout using a tamoxifen inducible Cre-LoxP system were tested to see general effects on the 
heart. Western blot analyses for Cops8 and Cops5 in the ventricular myocardial samples 
revealed that all knockouts show a significant downregulation of the protein respective to the 
gene directly knocked out (i.e., Cops8-cko mice have a 70% decrease in CSN8 protein levels, p-
value = 1.9 x 10-11; Cops5-cko mice have a 62% decrease in CSN5 protein levels, p-value = 2.8 x 
10-11; and Double-cko mice have an 87% decrease in CSN8 and a 60% decrease in CSN5 protein 
levels, p-value = 1.9 x 10-12, p-value = 5.1 x 10-11) as compared with MCM Cre controls (Figure 
4). When one subunit of this complex is downregulated, the other CSN subunits will be 
destabilized and subsequently degraded by the UPS55. This expected phenomenon is present in 
these models as well (i.e., Cops8-cko mice have a 49% decrease in CSN5 protein levels, p-value 
= 9.1 x 10-10; Cops5-cko mice have a 55% decrease in CSN8 protein levels, p-value = 6.2 x 10-10 






Figure 4. Western blot analyses for myocardial CSN8 and CSN5 in Cops8-cko, Cops5-cko, and 
Double-cko mice at 3 weeks after tamoxifen chow withdrawal. A, representative western blot 
images of the indicated proteins- CSN8, CSN5, and a stain-free total protein image used as a loading 
control (L.C.). B and C, the pooled densitometry data for CSN8 (B) and CSN5 (C). Each dot represents a 




3.2. Cops5-cko and Double-cko mice develop dilated cardiomyopathy before Cops8-cko 
Knocking out of the smallest and non-catalytic CSN subunit, Cops8, in mice causes extensive 
cardiomyocyte necroptosis, dilated cardiomyopathy, and shortened lifespan in mice20. At five 
weeks post tamoxifen treatment, a comparison of phenotypic differences between three CSN 
subunit cardiomyocyte-restricted knockout models: Cops8-cko, Cops5-cko, a Double-cko in vivo 
showed that Cops5-cko and Double-cko mice develop dilated cardiomyopathy before 
symptomology appears in Cops8-cko. As compared with MCM-Cre controls, all cko groups have 
reduced Ejection Fraction (EF) and Fractional Shortening (FS) indicative of impaired LV function 
(MCM-Cre controls: mean EF: 43.7%, FS: 21.6%; Cops8-cko: EF: 33.2%, p=8.4 x 10-4, FS: 16.1%, 
p=9.8 x 10-4; Cops5-cko: EF: 17%, p=1.6 x 10-10, FS: 7.7%, p=1.6 x 10-10; Double-cko: EF: 16.4%, 
p=1.6 x 10-10, FS: 7.5%, p=1.6 x 10-10) (Figure 5). However, when directly compared with Cops8-
cko, the Cops5-cko and Double-cko mice have significantly lower EF, FS, Stroke Volume (SV), 
Cardiac Output (CO), Left Ventricular Posterior Wall End Systole (LVPW;s), and Left Ventricular 
Posterior Wall End Diastole (LVPW;d) indicating impaired LV function and thinning of cardiac 
walls consistent with a dilated cardiomyopathy phenotype (Figure 5). All echocardiographic 
parameters are shown in Table 2. The results of these echocardiograms show that Cops5-cko 






Figure 5. Key parameters of the M-mode echocardiography recorded 3 weeks after tamoxifen chow 
withdrawal. Shown are Ejection Fraction (EF; A), Fractional Shortening (FS, B), Stroke Volume (SV, C), 
Cardiac Output (CO, D), End-Systolic Left Ventricular Posterior Wall Thickness (LVPW;s, E), and End-
Diastolic Left Ventricular Posterior Wall Thickness (LVPW;d, F). Each dot represents a mouse. MCM 
CTL (N=36), Cops8-cko (19), Cops5-cko (14), Double-cko (19); equal numbers of each sex were used. 
*p<0.01, **p<0.001, ***p<0.0001; n.s., not significant. 
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Body Weight (g) 27.8 ± 3.9 28.2 ± 5.9  26.3 ± 3.5 24.7 ± 3.7 
Heart Rate (BPM) 429.1 ± 48.4 442.3 ± 64.9 431.6 ± 68.5 435.5 ± 58.2 
LVID;s (mm) 3.4 ± 0.3 4.1 ± 0.8*** 4.6 ± 0.6*** 4.5 ± 0.6*** 
LVID;d (mm) 4.4 ± 0.3 4.8 ± 0.6** 4.9 ± 0.5** 4.9 ± 0.5** 
ESV (uL) 49.7 ± 11.5 77.5 ± 37.4** 97.3 ± 28.7*** 95.3 ± 27.1*** 
EDV (uL) 87.9 ± 14.5 110.9 ± 32.3** 115.9 ± 27.0** 112.6 ± 25.7** 
LV Mass (mg) 111.2 ± 27.6 140.5 ± 37.3** 115.1 ± 20.9 110.5 ± 36.8 
LVAW;s (mm) 0.68 ± 0.13 0.71 ± 0.14 0.60 ± 0.09 0.56 ± 0.15*, ## 
LVAW;d (mm) 0.68 ± 0.13 0.71 ± 0.14 0.60 ± 0.09 0.56 ± 0.15*, ## 
LVPW;s (mm) 0.80 ± 0.17 0.83 ± 0.18 0.64 ± 0.07**, ## 0.62 ± 0.14***, 
### 
LVPW;d (mm) 0.67 ± 0.11 0.72 ± 0.13 0.59 ± 0.06# 0.60 ± 0.14## 
EF (%) 43.7 ± 6.8 33.2 ± 14.3*** 17.0 ± 6.8***, ### 16.4 ± 8.8***, ### 
FS (%) 21.6 ± 4.0 16.1 ± 7.5*** 7.7 ± 3.2***, ### 7.5 ± 4.2***, ### 
SV (uL) 38.2 ± 7.6 33.4 ± 11.1 18.5 ± 5.4***, ### 17.4 ± 7.5***, ### 
CO (mL/min) 16.4 ± 3.7 14.8 ± 5.5 7.5 ± 2.4***, ### 7.6 ± 3.8***, ### 
Equal numbers of each sex were used. Mean ± SD; *p<0.01, **p<0.001, ***p<0.0001 compared 

















3.3. Cops5-cko and Double-cko mice have more severely shortened lifespans as than Cops8-
cko 
Kaplan-Meier survival analyses revealed shortened lifespans for all cko groups as compared to 
the MCM-Cre control group, where no animals from the MCM-Cre control group died during 
the timeframe analyzed. However, the post-tamoxifen lifespans of Cops5-cko and Double-cko 
mice, although comparable to each other (median=42 days for both), were both significantly 
shorter than the post-tamoxifen lifespans of the Cops8-cko mice (median=81 days; p<0.0001, 
Log-Rank test; Figure 7). These data show that the Cops5-cko and Double-cko mice have 
significantly decreased lifespan as compared to Cops8-cko, consistent with the difference in the 
severity of cardiomyopathy in these mice.  
 
 
Figure 7. Kaplan Meier Survival Curves for Cops8-cko, Cops5-cko, and Double-cko mice. N for each 




3.4. Cops5-cko and Double-cko mice have more extensive cardiomyocyte necrosis as 
compared to Cops8-cko 
Necrosis, a highly pro-inflammatory cell death, is morphologically distinct from apoptosis56. Cell 
membrane permeability and inflammation are important pathological events indicative of 
necrosis. In accordance with this, we observed about a 2.5-fold increase in the number of 
cardiomyocytes positive for Evans blue dye (EBD) uptake in Cops5-cko and Double-cko mice 
than in Cops8-cko or the MCM-Cre control mice, indicative of increased membrane 
permeability (Figure 8). High magnitude images were taken to verify that the dye was being up 
taken into the cells especially cardiomyocytes (Figure 9). We also observed about a 3.0-fold 
increase in the amount of myocardial CD45 proteins, which is a marker for leukocyte 
infiltration, in Cops5-cko and Double-cko mice than in Cops8-cko or the MCM-Cre control mice 
(Figure 10). These results, taken together, indicate that Cops5-cko and Double-cko mice have 
























Figure 8. EBD uptake assays in Cops8-cko, Cops5-cko and Double-cko mice. A, representative images 
of each ventricular tissue ring were reconstructed (x20 magnification) and used for quantification of 
EBD-positive area (red) and Alexa488-conjugated phalloidin to identify cardiomyocytes (green) and B, 
the pooled densitometry data. Mice collected 3 weeks after tamoxifen chow withdrawal. Each dot 
represents a mouse; N = 4-5 mice per group (2 males and 2 females). One-way ANOVA followed by the 





Figure 9. Representative high magnification micrographs of EBD uptake assays in Cops8-cko, Cops5-
cko and Double-cko mice. Representative images from ventricular tissue section to show the number 
of EBD-positive area (red), Alexa488-conjugated phalloidin to identify cardiomyocytes (green), and DAPI 






Figure 10. Cops5-cko and Double-cko mice showed increased CD45 proteins in the 
myocardium. A, representative blots are shown for CD45+ and a stain-free total protein 
image used as a loading control (L.C.) and B, the pooled densitometry data. Mice collected 3 
weeks after Tamoxifen chow withdrawal. Each dot represents a mouse; N = 4 (2 males, 2 
females) mice per group; one-way ANOVA followed by the Tukey test for pairwise 





3.5. Increased myocardial PKCδ protein levels in both Cops8-cko and Cops5-cko mice 
The pro-cell death enzyme PKCδ has been shown to be upregulated in different cardiac 
pathological models. Western blot analyses show that both Cops8-cko and Cops5-cko mice 
exhibit a similar 3.5-fold upregulation of myocardial PKCδ compared with the MCM control  
group (Cops8-cko vs. MCM, p=1.2 x 10-3; Cops5-cko vs. MCM, p=7.0 x 10-4; Figure 11). These 
results indicate that PKCδ is upregulated in both Cops8-cko and Cops5-cko mouse models.  
 
 
Figure 11. Western blot analysis for myocardial PKCδ at 3 weeks post tamoxifen withdrawal. A, 
representative images are shown for PKCδ and a stain-free total protein image used as a loading control 
(L.C.). B, the pooled densitometry data. Mice collected 3 weeks after tamoxifen chow withdrawal. Each 
dot represents a mouse; N = 4 (2 males, 2 females) mice per group; one-way ANOVA followed by the 





3.6. PKCδ haploinsufficiency attenuated dilated cardiomyopathy in Cops8-cko mice  
PKCδ is encoded by the PRKCD gene57. Other studies have shown that PKCδ inhibition is 
cardioprotective due to inhibition of apoptosis and necrosis58, 59. To determine the role of PKCδ 
upregulation in the pathophysiology of Cops8-cko, we cross-bred mice with perinatal Cops8-cko 
with mice with heterozygous Prkcd knockout (Prkcd+/-), analyzed the phenotypic difference 
between the resultant littermate Cops8-cko::Prkcd+/+ and Cops8-cko::Prkcd+/- mice, and 
obtained findings to be reported in the following subsections.  
3.6.1  PKCδ haploinsufficiency attenuates premature death seen in Cops8-cko mice  
Kaplan-Meier survival analyses revealed that PKCδ haploinsufficiency significantly increased 
lifespan in mice with perinatal Cops8-cko (Figure 12). The lifespans of perinatal Cops8-
cko::Prkcd+/+ mice (median lifespan=23 days) were significantly shorter as compared to the Cre 
CTL group (p=4.3 x 10-10), where no animals from the Cre CTL group died during the timeframe 
analyzed. However, the lifespans of Cops8-cko::Prkcd+/- (median survival: 26 days) were 11%  
longer than that of the Cops8-cko::Prkcd+/+ (p=0.04). These results indicate that PKCδ 
















Figure 12. PKCδ haploinsufficiency attenuates premature death seen in perinatal Cops8-cko mice. N 
for each genotype is followed in parenthesis of legend; equal numbers of each sex used. P=0.04, Cops8-





3.6.2  PKCδ haploinsufficiency attenuates cardiac malfunction induced by Cops8-cko  
To determine the impact of PKCδ deficiency on cardiac functioning within the Cops8-cko mouse 
model, echocardiography was performed at both 2 and 3 weeks of age for the Cre CTL, the 
Cops8-cko::Prkcd+/+, and the Cops8-cko::Prkcd+/- groups. At 2 weeks of age, both Cops8-
cko::Prkcd+/+ and Cops8-cko::Prkcd+/- groups showed increased end-systolic and end-diastolic LV 
diameters and reduced ejection fraction and fractional shortening, indicating impaired LV 
function consistent with dilated cardiomyopathy (Figure 13). However, Cops8-cko::Prkcd+/- have 
significantly thicker cardiac walls and increased cardiac mass. Stroke volume, cardiac output 
and end-diastolic volume (EDV) were all significantly greater in the Cops8-cko::Prkcd+/- as 
compared to the Cops8-cko::Prkcd+/+, which becomes more pronounced at 3 weeks of age, 
showing that the Cops8-cko::Prkcd+/- are better able to compensate (Figure 13). A complete list 
of echocardiographic parameters is shown in Table 3. The results from this echocardiography 
shows that Cops8-cko::Prkcd+/- have increased cardiac wall thickness and overall cardiac mass, 
which is better able to fill appropriate preload volumes leading to increased stroke volume and 
cardiac output. Overall, this echocardiography data indicates that PKCδ insufficiency is able to, 














Figure 13. PKCδ haploinsufficiency attenuates cardiac malfunction seen in Cops8-cko mice.  
A – F, M-mode echocardiography parameters: End-Systolic Left Ventricular Posterior Wall Thickness 
(LVPW;s/BW, A), End-Diastolic Left Ventricular Posterior Wall Thickness (LVPW;d/BW, B), LV Mass (LV 
Mass/BW, C), End-Diastolic Volume (EDV, D), Stroke Volume (SV, E), Cardiac Output (CO/BW, F). All 
parameters were normalized to body weight. Each dot represents a mouse; equal numbers of each 





Table 3. M-mode echocardiography data from the Prkcd+/- rescue experiment  
  
2 Weeks of Age 
 
































424.8 ± 42.1 392.8 ± 36.8 401.3 ± 
44.1 





0.51 ± 0.11*** 0.55 ± 0.09*** 0.39 ± 
0.07 





0.58 ± 0.11*** 0.64 ± 0.08*** 0.49 ± 
0.09 
0.63 ± 0.11*** 0.70 ± 0.09*** 
ESV/BW 
(uL/g) 
3.1 ± 0.7 6.9 ± 2.3*** 8.1 ± 2.9*** 4.2 ± 1.0 12.7 ± 4.0*** 14.2 ± 4.5*** 
EDV/BW 
(uL/g) 
5.6 ± 0.8 9.1 ± 2.1*** 11.0 ± 2.9***, ## 6.9 ± 1.2 14.0 ± 3.9*** 17.3 ± 4.6***, # 
LV Mass/BW 
(mg/g) 





0.067 ± 0.016 0.076 ± 0.019 0.061 ± 
0.018 





0.063 ± 0.015 0.070 ± 0.018 0.057 ± 
0.018 





0.066 ± 0.016 0.078 ± 0.022 0.063 ± 
0.021 





0.060 ± 0.012 0.073 ± 0.020*, # 0.054 ± 
0.011 
0.052 ± 0.010 0.051 ± 0.009 
EF (%) 46.5 ± 5.5 26.4 ± 9.5*** 28.7 ± 10.0*** 40.2 ± 
6.6 
13.7 ± 10.4*** 19.1 ± 8.7*** 
FS (%) 22.5 ± 4.4 12.1 ± 4.7*** 13.3 ± 5.0*** 18.8 ± 
3.9 
7.8 ± 5.5*** 8.8 ± 4.3*** 
SV (uL) 2.6 ± 0.6 2.2 ± 0.4* 3.0 ± 0.6*, ### 2.7 ± 0.5 1.3 ± 0.5*** 3.1 ± 0.7### 
CO (mL/min) 1.0 ± 0.2 0.9 ± 0.2* 1.2 ± 0.2* 1.1 ± 0.2 0.5 ± 0.2*** 1.2 ± 0.2### 
Parameters normalized to body weight are LVID;s, LVID;d, ESV, EDV, LV Mass, LVAW;s, LVAW;d, LVPW;s, 
LVPW;d. Equal numbers of each sex were used. Mean ± SD; *p<0.01, **p<0.001, ***p<0.0001 compared 
to Cre CTL; #p<0.01, ##p<0.001, ###p<0.0001 compared to Cops8-cko::Prkcd+/+.  
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3.6.3  PKCδ haploinsufficiency suppresses the activation of the necroptotic pathway induced 
by Cops8-cko in mice  
We have previously shown that cardiomyocyte necrosis induced by Cops8-cko belongs to 
necroptosis that is mediated by the RIPK1-RIPK3-MLKL pathway60. To test whether 
heterozygous PKCδ knockout alters the induction of the canonical necroptotic pathway by 
Cops8-cko, we collected ventricular myocardium from mice of the Prkcd+/- rescue 
experiment at 3 weeks of age and performed western blot analyses for main proteins of the 
RIPK1-RIPK3-MLKL pathway. As compared to Cre CTL, Cops8-cko::Prkcd+/+ mice exhibit 
significant upregulation of total Ripk1 (2.7-fold; p=9.8 x 10-4), total Ripk3 (1.6-fold; p=1.1 x 
10-4), total MLKL (3.9-fold; p=6.0 x 10-5), pS166-RIPK1 (1.7-fold; p=0.016 ), and pS345-MLKL 
(1.6-fold; p=1.7 x 10-3), consistent with activation of the canonical necroptotic pathway. As 
compared to Cre CTL, Cops8-cko::Prkcd+/- exhibited trends of upregulation of these 
necroptotic proteins, but the differences are not statistically significant. As compared to 
Cops8-cko::Prkcd+/+, Cops8-cko::Prkcd+/- exhibited a significant decrease in total Ripk3 (-
25%; p=0.046), total MLKL (-85%; p=0.016), and pS345-MLKL (-19%; p=0.047) and a trending 
decrease in pS166-RIPK1 (-28%; p=0.35). However, Cops8-cko::Prkcd+/- did exhibit a 
significant upregulation of Ser321-phosphorylated RIPK1 (pS321-RIPK1) (3.5-fold; p=1.1 x 
10-4) (Figures 14 and 15), which is known to serve as a checkpoint and inhibit the RIPK1 








Figure 14. Western blot analysis for the indicated proteins within the RIPK1-RIPK3-MLKL pathway. 
Shown are representative images of the western blots for myocardial levels of the indicated proteins. 
Total RIPK1, pS166-RIPK1, pS321-RIPK1, total RIPK3, total MLKL, pS345-MLKL, PKCδ, and CSN8 were 
immunoprobed in ventricular myocardial samples collected at 3 weeks of age. The image from Stain-
Free Total Protein imaging that was used as the loading control is shown immediately underneath the 
Western blot images that were derived from the gel imaged. Each lane represents a mouse; N > 4 mice 





Figure 15. Statistical analysis for the western blot analyses illustrated in Figure 14. Shown are the 
pooled densitometry data for total RIPK1 (A), pS166-RIPK1 (B), pS321-RIPK1 (C), total Ripk3 (D), total 
MLKL (E), pS345-MLKL (F), PKCδ (G), and Cops8 (H). All proteins probed were normalized to Stain-Free 
Total Proteins. Each dot represents a mouse; N > 4 mice per group, equal numbers of each sex were 
used; one-way ANOVA followed by the Tukey test for pairwise comparisons. *p<0.01, **p<0.001, 




Among the eight canonical subunits of the CSN, only Cops8 and Cops6 have been investigated 
in the heart with conditional gene targeting approaches20, 28. Mice with either prenatal or adult 
Cops8-cko displayed massive cardiomyocyte necrosis20, 22, but it remains undescribed whether 
cardiomyocyte necrosis occurs in the Cops6-cko mice28. Hence, we induced and verified three 
cardiomyocyte-specific CSN knockout mouse models, Cops8-cko, Cops5-cko, and Cops8+Cops5-
cko (Double-cko), to determine if cardiomyocyte necrosis also can be caused by ablation of 
another CSN subunit. This study revealed that the Cops5-cko and the Double-cko mice develop 
comparably massive cardiomyocyte necrosis, dilated cardiomyopathy, and a reduced lifespan 
that are qualitatively similar to the ultimate phenotypes of Cops8-cko mice; however, they 
appear seemingly earlier in Cops5-cko and Double-cko mice than in Cops8-cko. Furthermore, 
within the Cops8-cko and Cops5-cko, we noticed a marked upregulation of myocardial PKCδ. 
More importantly, the genetic ablation of the PKCδ upregulation significantly blunted the 
activation of the RIPK1-RIPK3-MLKL necroptotic pathway, attenuated cardiac malfunction, and 
delayed the premature death induced by Cops8-cko in mice. Hence, this study provides 
compelling evidence that Cullin-deneddylation activity is required for the CSN to suppress 
cardiomyocyte necrosis and demonstrates for the first time that PKCδ plays a crucial mediating 
role in the induction of cardiomyocyte necroptosis via the canonical pathway by COPS8 
deficiency.  These discoveries provide not only new mechanistic insight into the physiological 
requirement of the CSN for cardiomyocyte survival but also shine new light on the molecular 
links between perturbation of cardiac proteostasis and the genesis of heart failure, both of 
which have extremely important clinical implications.    
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4.1. Cullin-deneddylation activity is required for the CSN to suppress cardiomyocyte necrosis 
We have shown that Cops5-cko and Double-cko mice develop dilated cardiomyopathy before 
symptomology is apparent in Cops8-cko as demonstrated by key echocardiographic 
parameters. We have also shown that Cops5-cko and Double-cko mice have more severely 
shortened lifespans and have more extensive cardiomyocyte necrosis as compared to Cops8-
cko. The shared phenotype between these three models is likely due to loss of the CSN and 
subsequent Cullin deneddylation activity, which leads to cardiomyocyte necrosis in all three 
models. The current link between Cops/CSN deficiency and activation of the RIPK1-RIPK3-MLKL 
necroptotic pathway remains unclear, but inadequate protein quality control mechanisms offer 
exciting, plausible candidates. Our lab has verified that Cullin deneddylation is impaired in 
cardiomyocytes and that necroptosis is a mechanistic link between inadequate protein quality 
control mechanisms and the development of cardiac pathophysiology in Cops8-cko mice20. The 
Cops8-cko and Cops5-cko will be valuable models for studying the necrosis pathway in 
cardiomyocytes as well as finding potential therapeutics for the treatment of cardiovascular 
diseases.  
4.2. Upregulation of PKCδ contributes to activation of the necroptotic pathway by Cops8 
deficiency in cardiomyocytes. 
Cops8-cko and Cops5-cko mice both showed a 3.5-fold upregulation of the myocardial PKCδ 
protein, which has become known as a pro-death kinase. We have also demonstrated that 
PKCδ haploinsufficiency attenuated the dilated cardiomyopathy phenotype seen in Cops8-cko 
mice by increasing survival by 11%, by improving cardiac functioning of echocardiographic 
parameters such as stroke volume and cardiac output, and by suppressing the necroptotic 
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pathway that is typically induced by Cops8 deficiency.  Using a genetic approach to rescue 
Cops8-induced necroptosis, we have shown that PKCδ is contributing to activation of the 
necroptotic pathway in a mechanistic fashion that remains to be elucidated. It is unclear 
whether 1) PKCδ is playing its role more upstream, such as interacting directly with and 
upregulating TNFα in a feed-forward manner and by subsequent promotion of proinflammatory 
responses and reduces injury to cardiomyocytes independent of the RIPK1-RIPK3-MLKL 
pathway or is 2) PKCδ serving as a kinase and directly contributing to the phosphorylation of 
the specific phosphosites in RIPK1 and RIPK3 that are known to activate this necroptotic 
pathway, pS166-RIPK1 for example. Cell culture experiments done in smooth muscle cells offer 
some insight that PKCδ is playing an important role in chemokine expression as well as 
contributing to necroptosis via TNFα-RIPK1-RIPK3-MLKL pathway by transcriptional regulation 
of RIPK3 expression in smooth muscle cells62. However, there seems to be cell-specific functions 
so deciphering how PKCδ contributes to activation of the necroptotic pathway in 
cardiomyocytes remains to be answered.  
4.3. Significance and Clinical Implications 
Abnormalities within the UPS and ALP have been implicated in a wide spectrum of disease, 
lately within cardiovascular diseases that progress to heart failure63, 64.  This study directly adds 
to the literature of insufficient protein quality control and the pathogenesis of heart failure, to 
which current mechanistic insights are widely obscure. The Cops8-cko model is known to cause 
widespread and massive cardiomyocyte necrosis; however, this study shows the biological 
impact of inhibiting PKCδ and subsequent activation of the RIPK1-RIPK3-MLKL necroptotic 
pathway, to which has been shown to have positive therapeutic benefits previously29. 
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Therefore, current inhibitors for the RIPK1-RIPK3-MLKL necroptotic pathway like Necrostatin-1 
(RIPK1 kinase inhibitor), HS-1371 (RIPK3 inhibitor), GW806742X (MLKL inhibitor) could be 
effective in the clinical treatment of necroptotic cell death and ultimately in the treatment of 
heart failure.  Also, another lab has shown the reduction of Cops6 in human hearts and in 
animal models for ARVD/C that confirmed the pathological relevance of these studies in heart 
failure28. Although the researchers proposed an in-depth mechanism, they did not look at the 
deneddylation activity, holocomplex levels, or necroptosis. Still, it is a conceivable and a 
potential pathogenic factor within this disease since downregulation of any of the eight 
canonical subunits of the CSN will disrupt the CSN holocomplex formation and cause loss of 
Cullin deneddylation activity. Necroptosis is likely here but unknown. No published study 
besides past work from our lab shows the novelty of CSN knockouts in hearts and the primary 
link of necrosis, primarily necroptosis. 
Besides the cardiovascular clinical implications, this study also has direct, immediate 
implications in the cancer field. Because the activity of CRLs plays a critical and diverse role in 
cell cycle progression, gene transcription, apoptosis, signal transduction, and DNA replication, 
aberrant CRL activity is frequently associated with tumor cell division and survival7. Accordingly, 
the RING components of CRLs, RBX1 and RBX2 are known oncogenes that are commonly 
overexpressed in several human cancers65-67. Neddylation inhibitors that inhibit the activation 
and activity of CRLs, like MLN4924, are currently in clinical trials to treat certain types of skin, 
blood, and bone marrow cancers by suppressing proliferation and metastasis7, 68. Consistently, 
Cops5 is overexpressed in various primary tumors and overexpression of Cops5 causes p53 
degradation leading to apoptosis resistance which is a classic hallmark of cancer69. Accordingly, 
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a potent and selective inhibitor of Cops5, CSN5i-3, has become increasing popular in 
chemotherapeutics. However, past research from this lab20, as well as this current study 
directly caution the use of deneddylation or CSN inhibitors (trapping CRLs in a 
neddylated/deneddylated state), precisely due to the dramatic and rapid cardiotoxic effects. 
This study shows how cardiac function dramatically declines, reduces lifespan, and causes 
massive cardiomyocyte necroptosis caused by Cops deficiency and disruption of the catalytic 
dynamics. Although MLN4924 and CSN5i-3 show great promise in treating cancers, the decision 
to treat patients with these inhibitors needs to be weighed heavily since the cardiotoxic effects 
could outweigh the chemotherapeutic benefits; if treatment with these inhibitors is best, these 
patients should be closely monitored for overall cardiac health. 
4.4. Conclusions 
The UPS is one of the two major protein degradation pathways in cells, and UPS abnormalities 
have been implicated in a broad spectrum of human diseases. Since upwards of 80-90% of all 
proteins will be regulated through the UPS, there are broad implications in virtually all signaling 
pathways within the cell. Understanding the basic biology of this pathway and how critical 
regulators of the UPS, like CRLs and the CSN, fit into this will be vital to exploring potential 
therapeutic avenues to maintain or restore proteostasis for developing new therapeutic 
strategies. Here we have demonstrated that (1) Cullin-deneddylation activity is required for the 
CSN to suppress cardiomyocyte necrosis and (2) upregulation of PKCδ contributes to the 
activation of the RIPK1-RIPK3-MLKL pathway by Cops8 deficiency in cardiomyocytes in mice. 
Future research within this field will help our understanding of the molecular mechanisms 
underlying cardiomyocyte cell death to slow or possibly prevent pathological cardiac 
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remodeling and heart failure. A deeper understanding of what proteins manipulate the 




5. LIMITATIONS  
Limitations exist within this study, and future studies will need to be done to discover the 
potential mechanisms at play here. 1) Within this study, only a couple of parameters were used 
to examine necrosis, and more in-depth parameters will need to be detailed in future studies. 
Extensive parameters like specialized markers of myocardial damage, cell viability, and cell 
death should be used to verify these findings. Also, Cullin deneddylation activity is required to 
suppress cardiomyocyte necrosis60, and the Cops8-cko, Cops5-cko, and Double-cko induce 
similar necrosis suggesting a shared phenotype. However, we didn’t examine the Cullin 
deneddylation levels between the cko mouse models or if the necrosis noticed in the Cops5-cko 
and Double-cko is due to necroptosis, which remains to be confirmed. 2) Important conclusions 
drawn from this study using two different types of models, a perinatal and an adult inducible 
model, which both have potential drawbacks. The adult, inducible mouse model uses tamoxifen 
chow, which is known to have cardiotoxic effects in itself70. Some cardiotoxic effects were seen 
in the echocardiograms; however, no experimental or controls animals died from the current 
dosage used, and experimental animals were compared to appropriate controls tested at the 




6. FUTURE DIRECTIONS  
Many studies need to be completed to enrich our current understanding of the necroptotic cell 
death pathway within cardiomyocytes. 1) Because Cops5-cko and Double-cko mice develop 
cardiac pathology before Cops8-cko, it will also be essential to discover the exact mechanism as 
to why this is (Cops5 additional functions outside of holocomplex, protein turnover differences 
between Cops8 and Cops5, etc.). 2) At this moment, we have not examined Cullin 
deneddylation in Cops5-cko. It is also not known whether the necrosis noticed in the Cops5-cko 
and Double-cko mice belongs to necroptosis or whether other types of regulated necrosis might 
be coming into play (ferroptosis, pyroptosis, etc.). 3) More extensive parameters like Creatine 
Kinase MB (CK-MB), cardiac troponin I (cTnl), lactate dehydrogenase (LDH) release assays, as 
well as inflammatory cytokines panels (TNFα, IL6, …) should be used to verify the findings of this 
study. 4) It will also be essential to find the molecular link between PKCδ and the canonical 




LIST OF ABBREVIATIONS AND ACRONYMS  
 
CSN:    COP9 signalosome  
UPS:    Ubiquitin-Proteasome System 
CRLs:   Cullin Ring Ligases 
ARVD/C:  Arrythmogenic Right Ventricular Dysplasia/Cardiomyopathy 
ALP:    Autophagic-Lysosomal Pathway  
PQC:    Protein Quality Control 
cko   Cardiomyocyte-restricted knockout 
Cops8-cko:   cko of the Cops8 gene 
Cops5-cko:   cko of the Cops5 gene  
Double-cko:   cko of both the Cops8 and the Cops5 gene 
CTL:   Control group 
MCM:    MerCreMer, mutant estrogen receptor sandwiched Cre  
EBD:    Evans Blue Dye 
PKC:    Protein kinase C 
PRKCD:   The gene encoding the δ isoform of PKC 
LV:    Left Ventricle 
HR:   Heart Rate 
EF:    Ejection Fraction 
FS:    Fractional Shortening 
SV:    Stroke Volume 
CO:    Cardiac Output 
LVPW;s:   End-Systolic Left Ventricular Posterior Wall Thickness 
LVPW;d:   End-Diastolic Left Ventricular Posterior Wall Thickness 
LVAW;s  End-Systolic Left Ventricular Anterior Wall Thickness 
LVAW;d   End-Diastolic Left Ventricular Anterior Wall Thickness 
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LVID;s:   End-Systolic Left Ventricular Internal Diameter 
LVID;d:   End-Diastolic Left Ventricular Internal Diameter  
ESV:   End-Systolic Volume 
EDV:   End-Diastolic Volume 
pS166-RIPK1:  Ser166-Phosphorylated RIPK1 
pS321-RIPK1:  Ser321-Phosphorylated RIPK1 
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